Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized placebo-controlled crossover ascending-dose PK and safety study of NMB46 (regadenoson) in healthy Japanese men
jRCT2080223771Phase 1Completed
- Sponsor
- Nihon Medi-Physics Co., Ltd.
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of regadenoson (2 arms), sponsored by Nihon Medi-Physics Co., Ltd. Started Jan 2018; status: completed.
02
Drugs
regadenoson
Beyond the preview
Go deeper on jRCT2080223771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223771.